Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K170114
    Date Cleared
    2017-05-01

    (109 days)

    Product Code
    Regulation Number
    882.5805
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The MagVita TMS Therapy - w/MagPro R20 is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

    Device Description

    The MagVita TMS Therapy w/MagPro R20 is a computerized, electromechanical medical device that produces and delivers non-invasive, magnetic fields to induce electrical currents directed at regions of the cerebral cortex. The MagVita TMS Therapy w/MagPro R20 is indicated for Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

    Transcranial magnetic stimulation (TMS) is a non-invasive technique for stimulating brain and neural tissue. The principle of magnetic stimulation is implicit in Faraday's law. The pulses of current are generated with a circuit containing a capacitor connected to the stimulating coil. With the capacitor charged to a certain level, the conducting state will cause the discharging of the capacitor through the coil. A magnetic field is generated proportional to this current. The rapid change in the magnetic field induces a current in conducting materials e.g. the body tissue. If the current induced in the human body is of sufficient amplitude and duration, it will excite neurons.

    In the MagVita TMS therapy w/MagPro R20 TMS pulses are applied repetitively at a frequency of 10Hz. Such stimulation has been shown to be as effective as the predicate device in modulating cortical excitability. The observed and documented increase in cortical excitability after high frequency (10Hz) repetitive transcranial magnetic stimulation has been shown to persist beyond the duration of the train of stimulation. Repetitive Magnetic stimulation with the Mag Vita TMS therapy w/MagPro R20 is applied to the human brain on the left dorsolateral prefrontal cortex (DLPFC).

    The MagVita TMS Therapy w/MagPro R20 is an integrated system consisting of the following components:

    • . MagPro Stimulator and Trolley
      • MagPro R20 o
      • Trolley with holding arrangements o
    • Coils for MT determination and Depression Treatment .
      • o Coil MCF-B65
      • Marking apparatus for locating treatment area
        • Marking plate for Coil MCF-B65 o
        • Pen for marking, Cap, Ruler o
    • Patient head fixation

    .

    • Treatment Chair o
    • Vacuum Pump and Vacuum pillow o
    • Super Flexible Arm mounted on the trolley o
    • . Isolation Transformer
    AI/ML Overview

    This document is a 510(k) Summary for the MagVita TMS Therapy w/MagPro R20 device, comparing it to a predicate device, the MagVita TMS Therapy System (K150641).

    Based on the provided text, there is no acceptance criteria or study outlined to prove the device meets acceptance criteria.

    Instead, the document focuses on demonstrating substantial equivalence to a previously cleared predicate device. This means the manufacturer is asserting the new device is as safe and effective as a legally marketed device and does not raise new questions of safety or effectiveness.

    Therefore, many of the requested details about acceptance criteria and a specific study proving it are not present in this type of FDA submission. Here's what can be inferred or explicitly stated based on the document's content:


    1. Table of Acceptance Criteria and Reported Device Performance

    As noted, there are no explicit "acceptance criteria" presented in the document in the format of a performance study with defined thresholds. The document instead presents a comparison of the new device's performance characteristics to those of the predicate device to demonstrate substantial equivalence.

    CharacteristicMagVita TMS Therapy w/MagPro R20 (New Device)MagVita TMS Therapy System (Predicate Device) (K150641)Comparison Outcome (Implicit Acceptance)
    Intended Use / Indication for UseTreatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.Identical
    WaveformsBiphasicBiphasicIdentical
    Frequency Range0.1 - 20 pulses per second0.1 - 30 pulses per second or 0.1 - 100 pulses per second, depending on modelSimilar (within relevant therapeutic range)
    Preset range of % MT50% - 140%0% - 140%Similar (within relevant therapeutic range)
    Recommended Standard Treatment Intensity120% MT120% MTIdentical
    Repetition Rate10 Hz10 HzIdentical
    Train Duration4 sec4 secIdentical
    Interval between pulses26 sec26 secIdentical
    Number of pulses/session30003000Identical
    Output Stimulation Parameters (SMT units)Available Stimulation Amplitude in Standard Motor Threshold (SMT) unitsAvailable Stimulation Amplitude in Standard Motor Threshold (SMT) unitsIdentical concept
    Amplitude Range0 - 1.2 SMT0 - 1.7 SMTSimilar (within relevant therapeutic range)
    Pulse Width290 µs (±5%), Biphasic sinusoid waveform290 µs (±5%), Biphasic sinusoid waveformIdentical
    Coil ConfigurationFigure-of-eight coil, Air coreFigure-of-eight coil, Air coreIdentical
    CoolingLiquid coolingForced liquid coolingSimilar (both involve liquid cooling)
    Standards MetISO 13485:2012, IEC60601-1, IEC60601-1-2ISO 13485:2012, IEC60601-1, IEC60601-1-1, IEC60601-1-2Similar (compliance with key safety and quality standards)

    Implicit Acceptance Criteria: The device is "accepted" if it is shown to be substantially equivalent to the predicate device, meaning its differences do not raise new questions of safety or effectiveness. The document asserts that "all other identified differences between the two systems are minor and without any known impact on safety or efficacy."


    2. Sample Size Used for the Test Set and the Data Provenance

    This document does not describe a clinical study with a "test set" in the context of diagnostic accuracy, image interpretation, or treatment efficacy data from the new device. The data presented is a technical comparison of device specifications.

    The "non-clinical performance data" section refers to previous FDA clearances for components (K160280 for MagPro R20, K150641 for chair/arm/etc., K071821 for Coil MCF-B65). This indicates that the safety and performance of individual components were evaluated and cleared through separate processes, but it does not represent a specific "test set" for the entire integrated system in a clinical performance study.

    Data Provenance: The technical specifications are derived from the device's design and engineering. Any clinical data implicitly relied upon would be from trials that supported the original predicate device's clearance and the understanding of rTMS efficacy for Major Depressive Disorder, not new data for this specific 510(k) submission.


    3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts

    Not applicable. This is not a study requiring expert-established ground truth. The comparison is based on technical specifications and functional equivalence.


    4. Adjudication Method for the Test Set

    Not applicable. There is no clinical "test set" or adjudication process described for diagnostic outcomes.


    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done

    No. This document does not present an MRMC comparative effectiveness study. The submission is for substantial equivalence based on technical and functional comparison to a predicate device. The device is a therapeutic electromagnetic stimulator, not an imaging or diagnostic device typically subject to MRMC studies.


    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done

    Not applicable. The device is a therapeutic system with human interaction. While it includes software, it is not an "algorithm only" device in the sense of AI for diagnostic interpretation.


    7. The Type of Ground Truth Used

    Not applicable in the context of a "ground truth" for a diagnostic or AI performance study. The "ground truth" for this 510(k) submission is the established safety and effectiveness of the existing predicate device and the recognized scientific understanding of repetitive transcranial magnetic stimulation (rTMS) for Major Depressive Disorder as supported by clinical evidence for that class of devices.


    8. The Sample Size for the Training Set

    Not applicable. This device is not an AI/Machine Learning algorithm that undergoes a training phase with a labeled dataset in the typical sense. It is a hardware and software system for delivering a physical therapy.


    9. How the Ground Truth for the Training Set Was Established

    Not applicable for the same reasons as point 8.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1